Biogen Inc.
EMPAVELI
C3 glomerulopathy (C3G) or primary IC-MPGN
Resolved
675days ago
Phase 2 readout · Aug 31, 2024
What's at stake
Phase 2 trial results for EMPAVELI in C3 glomerulopathy (C3G) or primary IC-MPGN are due Aug 31, 2024. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“In the Phase 3 VALIANT study, EMPAVELI demonstrated a 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits (as measured by C3 staining by biopsy), compared to placebo.”